Long acting GLP-1 receptor agonist (injectable)
Albiglutide injection
ALBI_SC
Doses in this pooled treatment
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.69 (-1.73 to 1.22) | 0.25 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.24 (-2.02 to -0.24) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.26 (-2.26 to 0.51) | 0.64 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.93 (-1.85 to 0.23) | 0.42 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.13 (-7.28 to 5.61) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.06 (-2.69 to 6.12) | 0.25 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.92 (-4.21 to 8.50) | 0.32 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 0.03 (-5.08 to 5.05) | 0.20 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 13.60 (2.30 to 59.72) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 2.80 (0.62 to 9.48) | 0.55 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.14 (0.43 to 21.02) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.34 (0.06 to 1.46) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.82 (1.39 to 5.60) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.42 (0.64 to 3.06) | 0.54 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.12 (0.20 to 5.67) | 0.48 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.50 (-2.97 to 1.98) | 0.35 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Placebo | MD -0.31 (-12.40 to 11.97) | 0.38 |
| Type 2 diabetes (adults) | All cause mortality | longest follow-up | Placebo | HR 0.95 (0.60 to 1.56) | 0.34 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.78 (0.45 to 1.39) | 0.65 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.01 (0.82 to 1.29) | 0.46 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.60 (1.04 to 2.80) | 0.44 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.53 (0.96 to 2.45) | 0.52 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.73 (0.89 to 3.54) | 0.53 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.03 (0.71 to 1.52) | 0.63 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.02 (1.14 to 3.71) | 0.34 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.01 (0.25 to 3.24) | 0.33 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.88 (0.35 to 2.23) | 0.66 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.02 (0.25 to 4.00) | 0.44 |
Trials
- NCT02465515A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus2015 · 9,463 randomized
- NCT02229227Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study2014 · 814 randomized · 26 weeks
- NCT01733758A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus2013 · 494 randomized · 52 weeks
- NCT00838916A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.2009 · 779 randomized · 156 weeks
- NCT00849017A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus2009 · 309 randomized · 156 weeks
- NCT00518115A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus2007 · 361 randomized · 16 weeks